The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
How is failure-free survival impacted by belumosudil in cGvHD which has failed prior therapy?
Featured:
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Aleksandr Lazaryan, MD MPH PhD, Moffitt Cancer Center, Tampa, US. We asked, How is survival impacted by belumosudil in chronic GvHD (cGvHD) which has failed prior therapy?
How is failure-free survival impacted by belumosudil in cGvHD which has failed prior therapy?
In this video, Lazaryan comments on belumosudil, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor. He also discusses the phase IIa study KD025-208 (NCT02841995), and the ROCKstar trial (NCT03640481).